TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05551260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition
Description: Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition
Description: Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests
Study: NCT05478057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system
Description: we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system
Description: we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system
Description: we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
Study: NCT06117878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
Study: NCT05003934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT04863599

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
Study: NCT05478057

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system
Description: we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
Study: NCT06159777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: \*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Study: NCT06504407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bingo Educational Game
Description: The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
Study: NCT05285137

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection
Study: NCT05394012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3013
Description: Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: Two doses of 30 μg/0.3 mL at an interval of 28 days
Study: NCT04971993

Intervention type: DEVICE
Intervention: Wearable Cardiac Monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.

Intervention type: DEVICE
Intervention: Wearable Cardiac Monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.

Intervention type: DEVICE
Intervention: Wearable Cardiac Monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
Study: NCT06159777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: \*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Study: NCT05285137

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection
Study: NCT05121792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy
Description: The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
Study: NCT05094492

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Curodont Repair Fluoride Plus
Description: P11-4 self assembling peptide combined with fluoride
Study: NCT05285137

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection
Study: NCT05540210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measurement of PSP
Description: one or two blood samples
Study: NCT04689217

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal drug injection
Description: All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal drug injection
Description: All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal drug injection
Description: All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height
Study: NCT05352919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.
Study: NCT06005272

Intervention type: OTHER
Intervention: Questionnaire
Description: Interviewer assisted completion of questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: Interviewer assisted completion of questionnaire.
Study: NCT05352919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab-matching placebo
Description: Administered as specified in the treatment arm.
Study: NCT06464068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months.
Study: NCT05457764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms.
Study: NCT06260085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relatives vioce record
Description: In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message (Table 1) in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.
Study: NCT06349031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants
Description: As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants
Description: As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
Study: NCT06183424

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Stimulation
Description: 2 mA, 20 min, 5 days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Stimulation
Description: 2 mA, 20 min, 5 days
Study: NCT04737967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
Study: NCT05743257

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.

Intervention type: BEHAVIORAL
Intervention: Food diary supply
Description: Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.

Intervention type: BEHAVIORAL
Intervention: Food diary supply
Description: Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.

Intervention type: BEHAVIORAL
Intervention: Interviews (semi-structured)
Description: Sample of participants was interviewed about their food provisioning practice and living conditions.
Study: NCT05352919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab-matching placebo
Description: Administered as specified in the treatment arm.
Study: NCT04927416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Gallium-DOTATATE-PET/CT
Description: 68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.
Study: NCT05743257

Intervention type: BEHAVIORAL
Intervention: Interviews (semi-structured)
Description: Sample of participants was interviewed about their food provisioning practice and living conditions.

Intervention type: BEHAVIORAL
Intervention: air and noise
Description: Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal

Intervention type: BEHAVIORAL
Intervention: air and noise
Description: Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
Study: NCT05094492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifluorid 10 fluoride varnish
Description: 5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
Study: NCT05224310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS block, SAP block
Description: performing either PECS block or SAP block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS block, SAP block
Description: performing either PECS block or SAP block
Study: NCT04120038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Management for Amputee Rehabilitation using Technology [SMART]
Description: Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
Study: NCT06186180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device